Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADDORA: Adalimumab TDM in RA
NCT04194827Phase 4Recruiting
- Sponsor
- Reade Rheumatology Research Institute
- Start
- Mar 2020
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of adalimumab in rheumatoid arthritis (RA) (2 arms), sponsored by Reade Rheumatology Research Institute. Primary endpoint: Medical costs at 52 weeks. Started Mar 2020; status: recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04194827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04194827.